Literature DB >> 25548173

Inducible RNAi in vivo reveals that the transcription factor BATF is required to initiate but not maintain CD8+ T-cell effector differentiation.

Jernej Godec1, Glenn S Cowley2, R Anthony Barnitz3, Ozan Alkan, David E Root2, Arlene H Sharpe4, W Nicholas Haining5.   

Abstract

The differentiation of effector CD8(+) T cells is critical for the development of protective responses to pathogens and for effective vaccines. In the first few hours after activation, naive CD8(+) T cells initiate a transcriptional program that leads to the formation of effector and memory T cells, but the regulation of this process is poorly understood. Investigating the role of specific transcription factors (TFs) in determining CD8(+) effector T-cell fate by gene knockdown with RNAi is challenging because naive T cells are refractory to transduction with viral vectors without extensive ex vivo stimulation, which obscures the earliest events in effector differentiation. To overcome this obstacle, we developed a novel strategy to test the function of genes in naive CD8(+) T cells in vivo by creating bone marrow chimera from hematopoietic progenitors transduced with an inducible shRNA construct. Following hematopoietic reconstitution, this approach allowed inducible in vivo gene knockdown in any cell type that developed from this transduced progenitor pool. We demonstrated that lentivirus-transduced progenitor cells could reconstitute normal hematopoiesis and develop into naive CD8(+) T cells that were indistinguishable from wild-type naive T cells. This experimental system enabled induction of efficient gene knockdown in vivo without subsequent manipulation. We applied this strategy to show that the TF BATF is essential for initial commitment of naive CD8(+) T cells to effector development but becomes dispensable by 72h. This approach makes possible the study of gene function in vivo in unperturbed cells of hematopoietic origin that are refractory to viral transduction.

Entities:  

Keywords:  BATF; CD8 T cell; RNAi; transcription factor

Mesh:

Substances:

Year:  2014        PMID: 25548173      PMCID: PMC4299213          DOI: 10.1073/pnas.1413291112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

1.  Cutting edge: antigen-independent CD8 T cell proliferation.

Authors:  P Wong; E G Pamer
Journal:  J Immunol       Date:  2001-05-15       Impact factor: 5.422

2.  Molecular and functional profiling of memory CD8 T cell differentiation.

Authors:  Susan M Kaech; Scott Hemby; Ellen Kersh; Rafi Ahmed
Journal:  Cell       Date:  2002-12-13       Impact factor: 41.582

3.  Dynamic programming of CD8+ T lymphocyte responses.

Authors:  Marianne J B van Stipdonk; Gijs Hardenberg; Martijn S Bijker; Edward E Lemmens; Nathalie M Droin; Douglas R Green; Stephen P Schoenberger
Journal:  Nat Immunol       Date:  2003-03-17       Impact factor: 25.606

4.  Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity.

Authors:  Aimee L Jackson; Julja Burchard; Janell Schelter; B Nelson Chau; Michele Cleary; Lee Lim; Peter S Linsley
Journal:  RNA       Date:  2006-05-08       Impact factor: 4.942

Review 5.  CD8 T cell responses to infectious pathogens.

Authors:  Phillip Wong; Eric G Pamer
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

6.  Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen.

Authors:  H Pircher; K Bürki; R Lang; H Hengartner; R M Zinkernagel
Journal:  Nature       Date:  1989-11-30       Impact factor: 49.962

7.  Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.

Authors:  Jérôme Galon; Anne Costes; Fatima Sanchez-Cabo; Amos Kirilovsky; Bernhard Mlecnik; Christine Lagorce-Pagès; Marie Tosolini; Matthieu Camus; Anne Berger; Philippe Wind; Franck Zinzindohoué; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Franck Pagès
Journal:  Science       Date:  2006-09-29       Impact factor: 47.728

8.  Early programming of T cell populations responding to bacterial infection.

Authors:  R Mercado; S Vijh; S E Allen; K Kerksiek; I M Pilip; E G Pamer
Journal:  J Immunol       Date:  2000-12-15       Impact factor: 5.422

9.  A validated regulatory network for Th17 cell specification.

Authors:  Maria Ciofani; Aviv Madar; Carolina Galan; Maclean Sellars; Kieran Mace; Florencia Pauli; Ashish Agarwal; Wendy Huang; Christopher N Parkhurst; Michael Muratet; Kim M Newberry; Sarah Meadows; Alex Greenfield; Yi Yang; Preti Jain; Francis K Kirigin; Carmen Birchmeier; Erwin F Wagner; Kenneth M Murphy; Richard M Myers; Richard Bonneau; Dan R Littman
Journal:  Cell       Date:  2012-09-25       Impact factor: 41.582

10.  The transcription factor BATF operates as an essential differentiation checkpoint in early effector CD8+ T cells.

Authors:  Makoto Kurachi; R Anthony Barnitz; Nir Yosef; Pamela M Odorizzi; Michael A DiIorio; Madeleine E Lemieux; Kathleen Yates; Jernej Godec; Martin G Klatt; Aviv Regev; E John Wherry; W Nicholas Haining
Journal:  Nat Immunol       Date:  2014-03-02       Impact factor: 25.606

View more
  14 in total

Review 1.  In vivo RNAi screens: concepts and applications.

Authors:  Shane Crotty; Matthew E Pipkin
Journal:  Trends Immunol       Date:  2015-04-27       Impact factor: 16.687

Review 2.  Genetic screens to study the immune system in cancer.

Authors:  Kai W Wucherpfennig; Adam Nr Cartwright
Journal:  Curr Opin Immunol       Date:  2016-06-13       Impact factor: 7.486

Review 3.  Am I ready for CRISPR? A user's guide to genetic screens.

Authors:  John G Doench
Journal:  Nat Rev Genet       Date:  2017-12-04       Impact factor: 53.242

4.  Maintenance of macrophage transcriptional programs and intestinal homeostasis by epigenetic reader SP140.

Authors:  Stuti Mehta; D Alexander Cronkite; Megha Basavappa; Tahnee L Saunders; Fatemeh Adiliaghdam; Hajera Amatullah; Sara A Morrison; Jose D Pagan; Robert M Anthony; Pierre Tonnerre; Georg M Lauer; James C Lee; Sreehaas Digumarthi; Lorena Pantano; Shannan J Ho Sui; Fei Ji; Ruslan Sadreyev; Chan Zhou; Alan C Mullen; Vinod Kumar; Yang Li; Cisca Wijmenga; Ramnik J Xavier; Terry K Means; Kate L Jeffrey
Journal:  Sci Immunol       Date:  2017-03-03

5.  CRISPR Screens to Identify Regulators of Tumor Immunity.

Authors:  Martin W LaFleur; Arlene H Sharpe
Journal:  Annu Rev Cancer Biol       Date:  2021-12-23

6.  BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models.

Authors:  Yuki Kagoya; Munehide Nakatsugawa; Yuki Yamashita; Toshiki Ochi; Tingxi Guo; Mark Anczurowski; Kayoko Saso; Marcus O Butler; Cheryl H Arrowsmith; Naoto Hirano
Journal:  J Clin Invest       Date:  2016-08-22       Impact factor: 14.808

7.  BATF regulates the expression of Nfil3, Wnt10a and miR155hg for efficient induction of antibody class switch recombination in mice.

Authors:  Rosemary E Morman; Patrick G Schweickert; Stephen F Konieczny; Elizabeth J Taparowsky
Journal:  Eur J Immunol       Date:  2018-06-26       Impact factor: 5.532

8.  pMHC affinity controls duration of CD8+ T cell-DC interactions and imprints timing of effector differentiation versus expansion.

Authors:  Aleksandra J Ozga; Federica Moalli; Jun Abe; Jim Swoger; James Sharpe; Dietmar Zehn; Mario Kreutzfeldt; Doron Merkler; Jorge Ripoll; Jens V Stein
Journal:  J Exp Med       Date:  2016-10-31       Impact factor: 14.307

9.  Pravastatin activates activator protein 2 alpha to augment the angiotensin II-induced abdominal aortic aneurysms.

Authors:  Hui Ma; Wen-Jing Liang; Mei-Rong Shan; Xue-Qing Wang; Sheng-Nan Zhou; Yuan Chen; Tao Guo; Peng Li; Hai-Ya Yu; Chao Liu; Ya-Ling Yin; Yu-Lin Wang; Bo Dong; Xin-Yan Pang; Shuang-Xi Wang
Journal:  Oncotarget       Date:  2017-02-28

10.  The Transcription Factor Runx2 Is Required for Long-Term Persistence of Antiviral CD8+ Memory T Cells.

Authors:  Elizabeth Olesin; Ribhu Nayar; Priya Saikumar-Lakshmi; Leslie J Berg
Journal:  Immunohorizons       Date:  2018-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.